RHOJ and mature T-cell and NK-cell non-Hodgkin lymphoma: In our study, over 75% of patients with TFH-TCL, PTCL-NOS, and ATLL were CD5+ at the initial presentation, justifying that these CD5-directed adoptive cell therapies have the potential to significantly improve the outcomes of TCL patients.